Wagner R - Search Results

1

Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus.

Kuate S, Stahl-Hennig C, Stoiber H, Nchinda G, Floto A, Franz M, Sauermann U, Bredl S, Deml L, Ignatius R, Norley S, Racz P, Tenner-Racz K, Steinman RM, Wagner R, Uberla K. Kuate S, et al. Among authors: wagner r. Virology. 2006 Jul 20;351(1):133-44. doi: 10.1016/j.virol.2006.03.009. Epub 2006 Apr 17. Virology. 2006. PMID: 16616946 Free article.

2

Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.

Schirmbeck R, Deml L, Melber K, Wolf H, Wagner R, Reimann J. Schirmbeck R, et al. Among authors: wagner r. Vaccine. 1995 Jun;13(9):857-65. doi: 10.1016/0264-410x(94)00038-o. Vaccine. 1995. PMID: 7483809

3

Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles.

Wagner R, Deml L, Fliessbach H, Wanner G, Wolf H. Wagner R, et al. Virology. 1994 Apr;200(1):162-75. doi: 10.1006/viro.1994.1175. Virology. 1994. PMID: 7510434 Free article.

4

Induction of cytolytic T lymphocytes directed towards the V3 loop of the human immunodeficiency virus type 1 external glycoprotein gp120 by p55gag/V3 chimeric vaccinia viruses.

Wagner R, Böltz T, Deml L, Modrow S, Wolf H. Wagner R, et al. J Gen Virol. 1993 Jul;74 ( Pt 7):1261-9. doi: 10.1099/0022-1317-74-7-1261. J Gen Virol. 1993. PMID: 7687647 Free article.

5

Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).

Osterrieder N, Wagner R, Brandmüller C, Schmidt P, Wolf H, Kaaden OR. Osterrieder N, et al. Among authors: wagner r. Virology. 1995 Apr 20;208(2):500-10. doi: 10.1006/viro.1995.1181. Virology. 1995. PMID: 7747423 Free article.

6

Induction of a MHC class I-restricted, CD8 positive cytolytic T-cell response by chimeric HIV-1 virus-like particles in vivo: implications on HIV vaccine development.

Wagner R, Deml L, Schirmbeck R, Reimann J, Wolf H. Wagner R, et al. Behring Inst Mitt. 1994 Dec;(95):23-34. Behring Inst Mitt. 1994. PMID: 7755506 Review.

7

Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.

Wagner R, Deml L, Wolf H. Wagner R, et al. Antibiot Chemother (1971). 1994;46:48-61. doi: 10.1159/000423633. Antibiot Chemother (1971). 1994. PMID: 7826039 Review. No abstract available.

8

Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles.

Wagner R, Deml L, Schirmbeck R, Niedrig M, Reimann J, Wolf H. Wagner R, et al. Virology. 1996 Jun 1;220(1):128-40. doi: 10.1006/viro.1996.0293. Virology. 1996. PMID: 8659105 Free article.

9

A recombinant HIV-1 virus-like particle vaccine: from concepts to a field study.

Wagner R, Deml L, Teeuwsen V, Heeney J, Yiming S, Wolf H. Wagner R, et al. Antibiot Chemother (1971). 1996;48:68-83. doi: 10.1159/000425160. Antibiot Chemother (1971). 1996. PMID: 8726508 Review. No abstract available.

10

Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques.

Wagner R, Deml L, Notka F, Wolf H, Schirmbeck R, Reimann J, Teeuwsen V, Heeney J. Wagner R, et al. Intervirology. 1996;39(1-2):93-103. doi: 10.1159/000150480. Intervirology. 1996. PMID: 8957675 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,002 results

Search Page